{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:36:33Z","timestamp":1776728193582,"version":"3.51.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China,China","doi-asserted-by":"crossref","award":["82100594"],"award-info":[{"award-number":["82100594"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M731417"],"award-info":[{"award-number":["2023M731417"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-026-04892-1","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:23:22Z","timestamp":1773314602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic modulation of the gut-liver axis with faecalibacterium prausnitzii in metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1186","volume":"26","author":[{"given":"Han","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"5","key":"4892_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41575-025-01045-z","volume":"22","author":"CD Byrne","year":"2025","unstructured":"Byrne CD, Armandi A, Pellegrinelli V, et al. \u039cetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment. Nat Rev Gastroenterol Hepatol. 2025;22(5):314\u201328.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4892_CR2","doi-asserted-by":"publisher","unstructured":"Reid MV, Fredickson G, Mashek DG. Mechanisms coupling lipid droplets to MASLD pathophysiology. Hepatology. Published online Oct 30, 2024. https:\/\/doi.org\/10.1097\/HEP.0000000000001141.","DOI":"10.1097\/HEP.0000000000001141"},{"issue":"1","key":"4892_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2331460","volume":"16","author":"R Bened\u00e9-Ubieto","year":"2024","unstructured":"Bened\u00e9-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in metabolic-associated steatotic liver disease (MASLD). Gut Microbes. 2024;16(1):2331460.","journal-title":"Gut Microbes"},{"issue":"1","key":"4892_CR4","doi-asserted-by":"publisher","first-page":"2500099","DOI":"10.1080\/19490976.2025.2500099","volume":"17","author":"H Wu","year":"2025","unstructured":"Wu H, Chen J, Guo S, et al. Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease. Gut Microbes. 2025;17(1):2500099.","journal-title":"Gut Microbes"},{"issue":"6","key":"4892_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S2468-1253(24)00390-X","volume":"10","author":"MF Neurath","year":"2025","unstructured":"Neurath MF, Artis D, Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer. Lancet Gastroenterol Hepatol. 2025;10(6):573\u201392.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl","key":"4892_CR6","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","volume":"31","author":"H Saeed","year":"2025","unstructured":"Saeed H, D\u00edaz LA, Gil-G\u00f3mez A, et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S94\u2013111.","journal-title":"Clin Mol Hepatol"},{"key":"4892_CR7","doi-asserted-by":"publisher","first-page":"121614","DOI":"10.1016\/j.lfs.2023.121614","volume":"321","author":"L Luo","year":"2023","unstructured":"Luo L, Chang Y, Sheng L. Gut-liver axis in the progression of nonalcoholic fatty liver disease: from the microbial derivatives-centered perspective. Life Sci. 2023;321:121614.","journal-title":"Life Sci"},{"issue":"6","key":"4892_CR8","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","volume":"76","author":"JS Bajaj","year":"2022","unstructured":"Bajaj JS, Ng SC, Schnabl B. Promises of microbiome-based therapies. J Hepatol. 2022;76(6):1379\u201391.","journal-title":"J Hepatol"},{"issue":"1","key":"4892_CR9","doi-asserted-by":"publisher","first-page":"2226922","DOI":"10.1080\/19490976.2023.2226922","volume":"15","author":"M Koning","year":"2023","unstructured":"Koning M, Herrema H, Nieuwdorp M, et al. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies. Gut Microbes. 2023;15(1):2226922.","journal-title":"Gut Microbes"},{"issue":"Suppl","key":"4892_CR10","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","volume":"31","author":"H Saeed","year":"2025","unstructured":"Saeed H, D\u00edaz LA, Gil-G\u00f3mez A, et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease [J]. Clin Mol Hepatol. 2025;31(Suppl):S94-s111.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"4892_CR11","doi-asserted-by":"publisher","first-page":"2304159","DOI":"10.1080\/19490976.2024.2304159","volume":"16","author":"H Li","year":"2024","unstructured":"Li H, Wang XK, Tang M, et al. Bacteroides thetaiotaomicron ameliorates mouse hepatic steatosis through regulating gut microbial composition, gut-liver folate and unsaturated fatty acids metabolism. Gut Microbes. 2024;16(1):2304159.","journal-title":"Gut Microbes"},{"issue":"6","key":"4892_CR12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.clnu.2024.04.004","volume":"43","author":"Y Yang","year":"2024","unstructured":"Yang Y, Yang L, Wu J, et al. Optimal probiotic combinations for treating nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Clin Nutr. 2024;43(6):1224\u201339.","journal-title":"Clin Nutr"},{"issue":"1","key":"4892_CR13","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1038\/s41467-025-58500-3","volume":"16","author":"C Liu","year":"2025","unstructured":"Liu C, Zheng X, Ji J, et al. The carotenoid torularhodin alleviates NAFLD by promoting Akkermanisa muniniphila-mediated adenosylcobalamin metabolism. Nat Commun. 2025;16(1):3338.","journal-title":"Nat Commun"},{"issue":"1","key":"4892_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1907272","volume":"13","author":"MK Stoeva","year":"2021","unstructured":"Stoeva MK, Garcia-So J, Justice N, et al. Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease. Gut Microbes. 2021;13(1):1\u201328.","journal-title":"Gut Microbes"},{"issue":"4","key":"4892_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/ismej.2016.176","volume":"11","author":"M Lopez-Siles","year":"2017","unstructured":"Lopez-Siles M, Duncan SH, Garcia-Gil LJ, et al. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017;11(4):841\u201352.","journal-title":"ISME J"},{"issue":"7","key":"4892_CR16","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/gutjnl-2024-334338","volume":"74","author":"R Formiga","year":"2025","unstructured":"Formiga R, Sokol H. Faecalibacterium prausnitzii: one species with multiple potential implications in cancer research. Gut. 2025;74(7):1038\u20139.","journal-title":"Gut"},{"issue":"1","key":"4892_CR17","doi-asserted-by":"publisher","first-page":"2455503","DOI":"10.1080\/19490976.2025.2455503","volume":"17","author":"P Geng","year":"2025","unstructured":"Geng P, Zhao N, Zhou Y, et al. Faecalibacterium prausnitzii regulates carbohydrate metabolic functions of the gut microbiome in C57BL\/6 mice. Gut Microbes. 2025;17(1):2455503.","journal-title":"Gut Microbes"},{"issue":"7","key":"4892_CR18","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/ismej.2017.24","volume":"11","author":"E Munukka","year":"2017","unstructured":"Munukka E, Rintala A, Toivonen R, Nylund M, Yang B, Takanen A, et al. Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice. ISME J. 2017;11(7):1667\u201379.","journal-title":"ISME J"},{"issue":"14","key":"4892_CR19","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.3390\/nu14142945","volume":"14","author":"W Hu","year":"2022","unstructured":"Hu W, Gao W, Liu Z, Fang Z, Wang H, Zhao J, et al. Specific strains of Faecalibacterium prausnitzii ameliorate nonalcoholic fatty liver disease in mice in association with gut microbiota regulation. Nutrients. 2022;14(14):2945.","journal-title":"Nutrients"},{"issue":"14","key":"4892_CR20","doi-asserted-by":"publisher","first-page":"1123547","DOI":"10.3389\/fmicb.2023.1123547","volume":"16","author":"JH Shin","year":"2023","unstructured":"Shin JH, Lee Y, Song EJ, Lee D, Jang SY, Byeon HR, et al. Faecalibacterium prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet. Front Microbiol. 2023;16(14):1123547.","journal-title":"Front Microbiol"},{"key":"4892_CR21","doi-asserted-by":"publisher","unstructured":"Mart\u00edn R, Rios-Covian D, Huillet E, Auger S, Khazaal S, Berm\u00fadez-Humar\u00e1n LG, et al. Faecalibacterium: a bacterial genus with promising human health applications. FEMS Microbiol Rev. 2023;47(4):fuad039. https:\/\/doi.org\/10.1093\/femsre\/fuad039.","DOI":"10.1093\/femsre\/fuad039"},{"issue":"6","key":"4892_CR22","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/HEP.0000000000000474","volume":"78","author":"RM Carr","year":"2023","unstructured":"Carr RM, Li Y, Chau L, et al. An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations. Hepatology. 2023;78(6):1843\u201357.","journal-title":"Hepatology"},{"issue":"12","key":"4892_CR23","doi-asserted-by":"publisher","first-page":"e154722","DOI":"10.1172\/jci.insight.154722","volume":"7","author":"S Touch","year":"2022","unstructured":"Touch S, Godefroy E, Rolhion N, et al. Human CD4+CD8\u03b1+ Tregs induced by Faecalibacterium prausnitzii protect against intestinal inflammation. JCI Insight. 2022;7(12):e154722.","journal-title":"JCI Insight"},{"issue":"10","key":"4892_CR24","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s41374-022-00807-6","volume":"102","author":"T Sakuma","year":"2022","unstructured":"Sakuma T, Nakamura M, Chiba T, et al. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis. Lab Invest. 2022;102(10):1150\u20137.","journal-title":"Lab Invest"},{"issue":"15","key":"4892_CR25","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/jssc.201101121","volume":"35","author":"R Garc\u00eda-Villalba","year":"2012","unstructured":"Garc\u00eda-Villalba R, Gim\u00e9nez-Bastida JA, Garc\u00eda-Conesa MT, Tom\u00e1s-Barber\u00e1n FA, Carlos Esp\u00edn J, Larrosa M. Alternative method for gas chromatography-mass spectrometry analysis of short-chain fatty acids in faecal samples. J Sep Sci. 2012;35(15):1906\u201313.","journal-title":"J Sep Sci"},{"issue":"3","key":"4892_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/microorganisms13030675","volume":"13","author":"E M\u00fcnte","year":"2025","unstructured":"M\u00fcnte E, Viebahn G, Khurana A, Fujiki J, Nakamura T, Lang S, et al. Faecalibacterium prausnitzii is associated with disease severity in MASLD but Its supplementation does not improve diet-induced steatohepatitis in mice. Microorganisms. 2025;13(3):675.","journal-title":"Microorganisms"},{"issue":"1","key":"4892_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12964-023-01464-y","volume":"22","author":"HT Yang","year":"2024","unstructured":"Yang HT, Jiang ZH, Yang Y, Wu TT, Zheng YY, Ma YT, et al. Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe. Cell Commun Signal. 2024;22(1):54.","journal-title":"Cell Commun Signal"},{"issue":"80","key":"4892_CR28","doi-asserted-by":"publisher","first-page":"10794","DOI":"10.3389\/bjbs.2023.10794","volume":"21","author":"W Xuan","year":"2023","unstructured":"Xuan W, Ou Y, Chen W, Huang L, Wen C, Huang G, et al. Faecalibacterium prausnitzii improves lipid metabolism disorder and insulin resistance in type 2 diabetic mice. Br J Biomed Sci. 2023;21(80):10794.","journal-title":"Br J Biomed Sci"},{"key":"4892_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.psyneuen.2019.02.025","volume":"104","author":"Z Hao","year":"2019","unstructured":"Hao Z, Wang W, Guo R, Liu H. Faecalibacterium prausnitzii (ATCC 27766) has preventive and therapeutic effects on chronic unpredictable mild stress-induced depression-like and anxiety-like behavior in rats. Psychoneuroendocrinology. 2019;104:132\u201342.","journal-title":"Psychoneuroendocrinology"},{"issue":"489","key":"4892_CR30","doi-asserted-by":"publisher","first-page":"eaav0120","DOI":"10.1126\/scitranslmed.aav0120","volume":"11","author":"A Tirosh","year":"2019","unstructured":"Tirosh A, Calay ES, Tuncman G, Claiborn KC, Inouye KE, Eguchi K, et al. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Transl Med. 2019;11(489):eaav0120.","journal-title":"Sci Transl Med."},{"issue":"2","key":"4892_CR31","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1002\/ctm2.665","volume":"12","author":"Z Jia","year":"2022","unstructured":"Jia Z, Chen X, Chen J, Zhang L, Oprescu SN, Luo N, et al. ACSS3 in brown fat drives propionate catabolism and its deficiency leads to autophagy and systemic metabolic dysfunction. Clin Transl Med. 2022;12(2):e665.","journal-title":"Clin Transl Med"},{"issue":"3","key":"4892_CR32","doi-asserted-by":"publisher","first-page":"e25460","DOI":"10.1016\/j.heliyon.2024.e25460","volume":"10","author":"J Hu","year":"2024","unstructured":"Hu J, Li S, Zhong X, Wei Y, Sun Q, Zhong L. Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice. Heliyon. 2024;10(3):e25460.","journal-title":"Heliyon"},{"issue":"9","key":"4892_CR33","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1073\/pnas.081627898","volume":"98","author":"VR Holla","year":"2001","unstructured":"Holla VR, Adas F, Imig JD, Zhao X, Price E Jr, Olsen N, et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci U S A. 2001;98(9):5211\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4892_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/advances\/nmx009","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu H, Wang J, He T, Becker S, Zhang G, Li D, et al. Butyrate: a double-edged sword for health? Adv Nutr. 2018;9(1):21\u20139.","journal-title":"Adv Nutr"},{"issue":"1","key":"4892_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mi.2014.44","volume":"8","author":"J Park","year":"2015","unstructured":"Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 2015;8(1):80\u201393.","journal-title":"Mucosal Immunol"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-026-04892-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-04892-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-04892-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:44:39Z","timestamp":1776725079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12866-026-04892-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4892"],"URL":"https:\/\/doi.org\/10.1186\/s12866-026-04892-1","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"382"}}